| Cancer-related molecular mechanisms research | Lifetime | 109 | CN 40 | 99.44 |
| Ferroptosis and cancer prognosis | Lifetime | 68 | CN 22 | 98.76 |
| Circular RNAs in diseases | Lifetime | 94 | CN 49 | 99.17 |
| MicroRNA in disease regulation | Lifetime | 218 | CN 72 | 99.11 |
| Lung Cancer Treatments and Mutations | Lifetime | 479 | CN 19 | 98.93 |
| Lung Cancer Research Studies | Lifetime | 435 | CN 18 | 98.39 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 971 | CN 58 | 98.04 |
| Lung Cancer Diagnosis and Treatment | Lifetime | 775 | CN 33 | 98.09 |
| Cancer Mechanisms and Therapy | Lifetime | 311 | CN 44 | 96.75 |
| Metastasis and carcinoma case studies | Lifetime | 533 | CN 42 | 96.40 |
| Phytoestrogen effects and research | Lifetime | 596 | CN 41 | 92.77 |
| Hippo pathway signaling and YAP/TAZ | Lifetime | 973 | CN 101 | 86.32 |
| Tuberous Sclerosis Complex Research | Lifetime | 950 | CN 59 | 75.88 |
| Mechanisms of cancer metastasis | Lifetime | 908 | CN 205 | 59.73 |
| Cancer-related molecular mechanisms research | 2021-2025 | 80 | CN 57 | 99.17 |
| Ferroptosis and cancer prognosis | 2021-2025 | 69 | CN 52 | 98.61 |
| RNA modifications and cancer | 2021-2025 | 180 | CN 122 | 98.21 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 143 | CN 23 | 99.06 |
| Lung Cancer Diagnosis and Treatment | 2021-2025 | 120 | CN 25 | 98.48 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 355 | CN 57 | 98.63 |
| MicroRNA in disease regulation | 2021-2025 | 192 | CN 123 | 97.47 |
| Lung Cancer Research Studies | 2021-2025 | 141 | CN 22 | 98.11 |
| Circular RNAs in diseases | 2021-2025 | 130 | CN 97 | 96.87 |
| Cancer Genomics and Diagnostics | 2021-2025 | 747 | CN 55 | 95.52 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | 2021-2025 | 500 | CN 108 | 92.50 |
| Cancer Mechanisms and Therapy | 2021-2025 | 197 | CN 80 | 89.43 |
| Cancer Cells and Metastasis | 2021-2025 | 542 | CN 112 | 88.32 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 920 | CN 127 | 89.64 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 752 | CN 304 | 86.00 |
| Peptidase Inhibition and Analysis | 2021-2025 | 870 | CN 265 | 86.94 |
| Colorectal and Anal Carcinomas | 2021-2025 | 719 | CN 98 | 85.43 |
| Hippo pathway signaling and YAP/TAZ | 2021-2025 | 212 | CN 96 | 79.05 |
| Cancer-related Molecular Pathways | 2021-2025 | 580 | CN 112 | 78.82 |
| Cancer-related gene regulation | 2021-2025 | 830 | CN 568 | 78.70 |
| Medical Imaging and Pathology Studies | 2021-2025 | 836 | CN 113 | 74.92 |
| Nuclear Receptors and Signaling | 2021-2025 | 685 | CN 161 | 54.81 |
| Histiocytic Disorders and Treatments | 2021-2025 | 756 | CN 100 | 34.41 |
